Allergan's Off-Label Suit Against FDA Will Continue Despite Botox Approval For Spasticity
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan is continuing to press for a court order that FDA's restrictions on off-label promotion are unconstitutional; a court hearing in the case is set for April 26.
You may also be interested in...
Off-Label Promotion: FDA Court Filing Says It Must Retain Enforcement Flexibility, Citing Harms From Premarin And ESAs
FDA adamantly rejected Allergan's proposals to loosen restrictions on off-label drug promotion in a further response to Allergan's suit against the agency
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.